Please use this identifier to cite or link to this item:
Title: COVID-19-associated mucormycosis and treatments
Authors: Subramaniyan, Vetriselvan
Fuloria, Shivkanya
Darnal, Hari Kumar
Meenakshi, Dhanalekshmi Unnikrishnan
Sekar, Mahendran
Rusli Nordin
Chakravarthi, Srikumar
Sathasivam, Kathiresan V.
Khan, Shah Alam
Wu, Yuan Seng
Kumari, Usha
Sudhakar, Kalvatala
Malviya, Rishabha
Sharma, Vipin Kumar
Fuloria, Neeraj Kumar
Keywords: COVID-19
Issue Date: Sep-2021
Publisher: Wolters Kluwer Medknow Publications
Citation: Fuloria, S., Fuloria, N., Subramaniyan, V., Darnal, H., Meenakshi, D., Sekar, M., Rusli Nordin, Chakravarthi, S., Sathasivam, K., Khan, S., Wu, Y., Kumari, U., Sudhakar, K., Malviya, R., & Sharma, V. (2021). COVID-19-associated mucormycosis and treatments. Asian Pacific Journal of Tropical Medicine, 14(9), 401.
Abstract: In the current pandemic, COVID-19 patients with predisposing factors are at an increased risk of mucormycosis, an uncommon angioinvasive infection that is caused by fungi with Mucor genus which is mainly found in plants and soil. Mucormycosis development in COVID-19 patient is related to various factors, such as diabetes, immunocompromise and neutropenia. Excessive use of glucocorticoids for the treatment of critically ill COVID-19 patients also leads to opportunistic infections, such as pulmonary aspergillosis. COVID-19 patients with mucormycosis have a very high mortality rate. This review describes the pathogenesis and various treatment approaches for mucormycosis in COVID-19 patients, including medicinal plants, conventional therapies, adjunct and combination therapies
ISSN: 19957645
Appears in Collections:Journal Articles

Files in This Item:
File Description SizeFormat 
COVID-19-associated mucormycosis and treatments.pdf396.58 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.